JEIL PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
Clinical Trials
35
Active:0
Completed:28
Trial Phases
5 Phases
Phase 1:21
Phase 2:3
Phase 3:6
+2 more phases
Drug Approvals
16
PHILIPPINES:16
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Phase 1
21 (63.6%)Phase 3
6 (18.2%)Phase 2
3 (9.1%)Not Applicable
2 (6.1%)Phase 4
1 (3.0%)Observationa Study is a Prospective and Multi-institutional Observational Study.
Completed
- Conditions
- Erosive Reflux DiseaseHeartburnAcid Regurgitation
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5536
- Registration Number
- NCT06952855
- Locations
- 🇰🇷
Goodbreath Medical Center, Seoul, Gyeonggi-do, Korea, Republic of
To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: JLP-2004 qd
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06431399
- Locations
- 🇰🇷
Chungbuk National University Hospital, Chungju, Seowon-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06171880
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06169059
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
Phase 1
Completed
- Conditions
- Healthy Adult
- Interventions
- Drug: SGLT2 inhibitor
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06165965
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found